标题
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
作者
关键词
-
出版物
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 81, Issue 16, Pages 1553-1564
出版商
Elsevier BV
发表日期
2023-03-07
DOI
10.1016/j.jacc.2023.02.018
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey
- (2021) Konstantinos C Koskinas et al. European Journal of Preventive Cardiology
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- (2021) Frank L J Visseren et al. EUROPEAN HEART JOURNAL
- Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
- (2021) Christopher P. Cannon et al. JAMA Cardiology
- A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
- (2021) Thomas J. Tucker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care
- (2021) Barbara Iyen et al. Open Heart
- Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
- (2020) Konstantinos C Koskinas et al. European Journal of Preventive Cardiology
- DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe
- (2020) Jane K. Stock ATHEROSCLEROSIS
- Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry
- (2018) Krzysztof Dyrbuś et al. PHARMACOLOGICAL RESEARCH
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease
- (2018) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients
- (2016) Anselm K. Gitt et al. ATHEROSCLEROSIS
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
- (2016) Henry N. Ginsberg et al. CARDIOVASCULAR DRUGS AND THERAPY
- Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
- (2016) Maciej Banach et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
- (2013) Evan A. Stein et al. Current Atherosclerosis Reports
- Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysis
- (2012) Mark Lemstra et al. CANADIAN JOURNAL OF CARDIOLOGY
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- APCSK9Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
- (2008) Sekar Kathiresan NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started